The EU Commission announces interim measures following a breach of the standstill obligation between two healthcare companies specialized in genomic sequencing (Illumina / Grail)

Mergers: The Commission adopts a Statement of Objections in view of adopting interim measures following Illumina's early acquisition of GRAIL* The European Commission has sent a Statement of Objections to Illumina and GRAIL informing them of the interim measures it intends to adopt following the companies' alleged breach of the standstill obligation under the EU Merger Regulation. These measures aim to restore and maintain effective competition while the Commission's review of the acquisition of GRAIL by Illumina is pending. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Illumina and GRAIL completed their merger, while our investigation is still ongoing. Under our rules, companies have to wait for the Commission's clearance before implementing

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

European Commission, The EU Commission announces interim measures following a breach of the standstill obligation between two healthcare companies specialized in genomic sequencing (Illumina / Grail), 20 septembre 2021, e-Competitions October 2021, Art. N° 102346

Visites 442

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues